Literature DB >> 8497879

Primary diagnosis predicts prognosis of lung transplant candidates.

A M Hayden1, R C Robert, J M Kriett, C M Smith, K Nicholson, S W Jamieson.   

Abstract

Optimal timing for consideration of lung transplantation remains unknown. This study examined survival in patients with end-stage lung disease awaiting transplantation. Primary disease group and relevant indicators were evaluated. Ninety-three patients who met selection criteria for lung transplantation were included in this retrospective review. Of this total, 31% underwent transplantation, 38% remain waiting, and 31% died. Results demonstrate that the six-month actuarial survival rate was 89% for Eisenmenger's syndrome, 81% for emphysema, 74% for cystic fibrosis, 60% for primary pulmonary hypertension, and 38% for interstitial lung disease. Parameters found to be significant included a higher mean right atrial pressure in primary pulmonary hypertension patients who died awaiting transplantation, and lower forced expiratory volume in one second and forced vital capacity measurements in cystic fibrosis patients who died awaiting transplantation. We conclude that primary disease significantly affects survival in candidates awaiting transplantation. Reliable indicators predictive of survival are not available. Earlier referral for consideration of lung transplantation is recommended.

Entities:  

Mesh:

Year:  1993        PMID: 8497879     DOI: 10.1097/00007890-199305000-00019

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Functional improvement in patients with idiopathic pulmonary fibrosis undergoing single lung transplantation.

Authors:  Adalberto Sperb Rubin; Douglas Zaione Nascimento; Letícia Sanchez; Guilherme Watte; Arthur Rodrigo Ronconi Holand; Derrick Alexandre Fassbind; José Jesus Camargo
Journal:  J Bras Pneumol       Date:  2015 Jul-Aug       Impact factor: 2.624

Review 2.  Pulmonary transplantation.

Authors:  R D Davis; M K Pasque
Journal:  Ann Surg       Date:  1995-01       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.